A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer

R. T. Eagan, T. R. Fleming, S. Frytak, E. T. Creagan, J. N. Ingle, L. K. Kvols

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Forty-one patients with advanced squamous cell lung cancer and no prior chemotherapy were entered in a prospectively randomized trial comparing dianhydrogalactitol plus Adriamycin (DA) versus DA plus cis-dichloro-diammineplatinum (II) (DAP). The DAP regimen was superior to the DA regimen in regression rate (53% versus 27%), median regression duration (255 versus 122 days), median time to tumor progression (approximately 175 versus 58 days), and median survival time (185 versus 126 days). Patients who were > 60 years old responded particularly well to the DAP regimen and accounted for most of the survival advantage. Nausea, vomiting, and myelosuppression were more frequent and severe with the DAP regimen. This study seems to indicate a role of cis-dichlorodiammineplatinum(II) in patients with advanced squamous cell lung cancer. The particular advantage noted for older patients needs further evaluation.

Original languageEnglish (US)
Pages (from-to)87-91
Number of pages5
JournalCancer Treatment Reports
Volume64
Issue number1
StatePublished - 1980
Externally publishedYes

Fingerprint

Dianhydrogalactitol
Squamous Cell Neoplasms
Cisplatin
Lung Neoplasms
Doxorubicin
dipeptidyl peptidase II
Survival
Nausea
Vomiting
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eagan, R. T., Fleming, T. R., Frytak, S., Creagan, E. T., Ingle, J. N., & Kvols, L. K. (1980). A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. Cancer Treatment Reports, 64(1), 87-91.

A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. / Eagan, R. T.; Fleming, T. R.; Frytak, S.; Creagan, E. T.; Ingle, J. N.; Kvols, L. K.

In: Cancer Treatment Reports, Vol. 64, No. 1, 1980, p. 87-91.

Research output: Contribution to journalArticle

Eagan, RT, Fleming, TR, Frytak, S, Creagan, ET, Ingle, JN & Kvols, LK 1980, 'A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer', Cancer Treatment Reports, vol. 64, no. 1, pp. 87-91.
Eagan RT, Fleming TR, Frytak S, Creagan ET, Ingle JN, Kvols LK. A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. Cancer Treatment Reports. 1980;64(1):87-91.
Eagan, R. T. ; Fleming, T. R. ; Frytak, S. ; Creagan, E. T. ; Ingle, J. N. ; Kvols, L. K. / A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. In: Cancer Treatment Reports. 1980 ; Vol. 64, No. 1. pp. 87-91.
@article{c27090fa549e4fbfa7ef8c652feb35ab,
title = "A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer",
abstract = "Forty-one patients with advanced squamous cell lung cancer and no prior chemotherapy were entered in a prospectively randomized trial comparing dianhydrogalactitol plus Adriamycin (DA) versus DA plus cis-dichloro-diammineplatinum (II) (DAP). The DAP regimen was superior to the DA regimen in regression rate (53{\%} versus 27{\%}), median regression duration (255 versus 122 days), median time to tumor progression (approximately 175 versus 58 days), and median survival time (185 versus 126 days). Patients who were > 60 years old responded particularly well to the DAP regimen and accounted for most of the survival advantage. Nausea, vomiting, and myelosuppression were more frequent and severe with the DAP regimen. This study seems to indicate a role of cis-dichlorodiammineplatinum(II) in patients with advanced squamous cell lung cancer. The particular advantage noted for older patients needs further evaluation.",
author = "Eagan, {R. T.} and Fleming, {T. R.} and S. Frytak and Creagan, {E. T.} and Ingle, {J. N.} and Kvols, {L. K.}",
year = "1980",
language = "English (US)",
volume = "64",
pages = "87--91",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer

AU - Eagan, R. T.

AU - Fleming, T. R.

AU - Frytak, S.

AU - Creagan, E. T.

AU - Ingle, J. N.

AU - Kvols, L. K.

PY - 1980

Y1 - 1980

N2 - Forty-one patients with advanced squamous cell lung cancer and no prior chemotherapy were entered in a prospectively randomized trial comparing dianhydrogalactitol plus Adriamycin (DA) versus DA plus cis-dichloro-diammineplatinum (II) (DAP). The DAP regimen was superior to the DA regimen in regression rate (53% versus 27%), median regression duration (255 versus 122 days), median time to tumor progression (approximately 175 versus 58 days), and median survival time (185 versus 126 days). Patients who were > 60 years old responded particularly well to the DAP regimen and accounted for most of the survival advantage. Nausea, vomiting, and myelosuppression were more frequent and severe with the DAP regimen. This study seems to indicate a role of cis-dichlorodiammineplatinum(II) in patients with advanced squamous cell lung cancer. The particular advantage noted for older patients needs further evaluation.

AB - Forty-one patients with advanced squamous cell lung cancer and no prior chemotherapy were entered in a prospectively randomized trial comparing dianhydrogalactitol plus Adriamycin (DA) versus DA plus cis-dichloro-diammineplatinum (II) (DAP). The DAP regimen was superior to the DA regimen in regression rate (53% versus 27%), median regression duration (255 versus 122 days), median time to tumor progression (approximately 175 versus 58 days), and median survival time (185 versus 126 days). Patients who were > 60 years old responded particularly well to the DAP regimen and accounted for most of the survival advantage. Nausea, vomiting, and myelosuppression were more frequent and severe with the DAP regimen. This study seems to indicate a role of cis-dichlorodiammineplatinum(II) in patients with advanced squamous cell lung cancer. The particular advantage noted for older patients needs further evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0018853167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018853167&partnerID=8YFLogxK

M3 - Article

C2 - 6991107

AN - SCOPUS:0018853167

VL - 64

SP - 87

EP - 91

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -